[go: up one dir, main page]

CA3147679A1 - Methodes de traitement de troubles psychologiques et cerebraux - Google Patents

Methodes de traitement de troubles psychologiques et cerebraux Download PDF

Info

Publication number
CA3147679A1
CA3147679A1 CA3147679A CA3147679A CA3147679A1 CA 3147679 A1 CA3147679 A1 CA 3147679A1 CA 3147679 A CA3147679 A CA 3147679A CA 3147679 A CA3147679 A CA 3147679A CA 3147679 A1 CA3147679 A1 CA 3147679A1
Authority
CA
Canada
Prior art keywords
disorder
syndrome
personality
psilocybin
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3147679A
Other languages
English (en)
Inventor
Scott Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
Original Assignee
University of Maryland Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore filed Critical University of Maryland Baltimore
Publication of CA3147679A1 publication Critical patent/CA3147679A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/078—Psilocybe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des procédés de prévention ou de traitement d'un trouble psychologique. Un agoniste de la sérotonine ou un agoniste des récepteurs de la sérotonine est administré séparément, séquentiellement ou simultanément en combinaison avec un antagoniste du récepteur 2A de la sérotonine.
CA3147679A 2019-08-13 2020-08-13 Methodes de traitement de troubles psychologiques et cerebraux Pending CA3147679A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886090P 2019-08-13 2019-08-13
US62/886,090 2019-08-13
PCT/US2020/046149 WO2021030571A1 (fr) 2019-08-13 2020-08-13 Méthodes de traitement de troubles psychologiques et cérébraux

Publications (1)

Publication Number Publication Date
CA3147679A1 true CA3147679A1 (fr) 2021-02-18

Family

ID=74569306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3147679A Pending CA3147679A1 (fr) 2019-08-13 2020-08-13 Methodes de traitement de troubles psychologiques et cerebraux

Country Status (11)

Country Link
US (2) US20220273680A1 (fr)
EP (1) EP4013403A4 (fr)
JP (1) JP2022544379A (fr)
KR (1) KR20220047327A (fr)
CN (1) CN114599355A (fr)
AU (1) AU2020328618A1 (fr)
BR (1) BR112022002723A2 (fr)
CA (1) CA3147679A1 (fr)
IL (1) IL290455A (fr)
MX (1) MX2022001751A (fr)
WO (1) WO2021030571A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3713568A1 (fr) 2017-10-26 2020-09-30 Consejo Superior de Investigaciones Cientificas (CSIC) Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
BR112022017097A2 (pt) * 2020-02-28 2022-11-16 Univ Basel Composição e uso da composição
PH12022553135A1 (en) 2020-05-19 2024-03-04 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
EP4155306A1 (fr) 2021-01-15 2023-03-29 Beckley Psytech Limited Analogue neuroactif d'ergoline
TW202304423A (zh) * 2021-04-01 2023-02-01 美商泰仁生物科學公司 與致幻劑及血清素受體調節劑相關之方法及組合物
EP4346788A4 (fr) 2021-06-03 2025-04-30 Arcadia Medicine, Inc. Compositions entactogènes énantiomères et leurs méthodes d'utilisation
US11801256B2 (en) 2021-06-08 2023-10-31 Universitätsspital Basel Antidepressant-psilocybin co-treatment to assist psychotherapy
TW202317545A (zh) 2021-07-07 2023-05-01 美商泰仁生物科學公司 N,n-二甲基色胺及相關致幻劑及其用途
CN113527175B (zh) * 2021-08-16 2023-01-03 旦多多(苏州)食品有限公司 一种巴旦木中氮甲基5-羟色胺的分离方法及应用
WO2023043942A1 (fr) * 2021-09-15 2023-03-23 Blue Sun Mycology Group, LLC Procédés de production d'organismes cybrides et hybrides somatiques
EP4159192A1 (fr) 2021-09-30 2023-04-05 Biomind Labs Inc Spray nasal à base de diméthyltriptamine pour le traitement personnalisé des troubles neurologiques et psychiatriques
CA3237988A1 (fr) 2021-11-12 2023-05-19 Terran Biosciences Inc. Psilocybine et o-acetylpsilocine, leurs sels et formes a l'etat solide
US20250129025A1 (en) * 2021-12-10 2025-04-24 GATC Health Corp Methods of treating ptsd and neurological disorders
EP4486448A1 (fr) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-cristaux ou sels comprenant de la psilocine
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
EP4590292A1 (fr) * 2022-09-21 2025-07-30 Axsome Therapeutics, Inc. Composés et combinaisons de ceux-ci pour le traitement d'états neurologiques et psychiatriques
CN120676954A (zh) * 2023-03-02 2025-09-19 本田技研工业株式会社 组合物
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101677971A (zh) * 2007-03-19 2010-03-24 阿卡蒂亚药品公司 5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
NL2018190B1 (en) * 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
EP3713568A1 (fr) * 2017-10-26 2020-09-30 Consejo Superior de Investigaciones Cientificas (CSIC) Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
BR112022017097A2 (pt) * 2020-02-28 2022-11-16 Univ Basel Composição e uso da composição
US11717517B2 (en) * 2020-04-13 2023-08-08 Universitatsspital Basel LSD dose identification

Also Published As

Publication number Publication date
US20220273680A1 (en) 2022-09-01
US20230000885A1 (en) 2023-01-05
EP4013403A4 (fr) 2023-08-30
AU2020328618A1 (en) 2022-03-31
EP4013403A1 (fr) 2022-06-22
WO2021030571A1 (fr) 2021-02-18
BR112022002723A2 (pt) 2022-07-19
JP2022544379A (ja) 2022-10-18
KR20220047327A (ko) 2022-04-15
CN114599355A (zh) 2022-06-07
IL290455A (en) 2022-04-01
MX2022001751A (es) 2022-06-02

Similar Documents

Publication Publication Date Title
US20230000885A1 (en) Methods of Treating Psychological and Brain Disorders
Zhang et al. Comparison of ketamine, 7, 8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression
Hussaini et al. Wnt signaling in neuropsychiatric disorders: ties with adult hippocampal neurogenesis and behavior
Wu et al. Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer's disease
Xu et al. Activation of liver X receptors prevents emotional and cognitive dysfunction by suppressing microglial M1-polarization and restoring synaptic plasticity in the hippocampus of mice
Cisternas et al. Presymptomatic treatment with andrographolide improves brain metabolic markers and cognitive behavior in a model of early-onset Alzheimer’s disease
Zhao et al. Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model
Xu et al. Orbitofrontal cortex 5-HT2A receptor mediates chronic stress-induced depressive-like behaviors and alterations of spine density and Kalirin7
Navarro et al. Alpha7 nicotinic receptor activation protects against oxidative stress via heme-oxygenase I induction
Ligsay et al. Review of targeted treatments in fragile X syndrome
RS62516B1 (sr) Primena r-ketamina i njegove soli kao farmaceutskih proizvoda
Ren et al. Effects of TrkB agonist 7, 8-dihydroxyflavone on sensory gating deficits in mice after administration of methamphetamine
Takeda et al. Molar loss and powder diet leads to memory deficit and modifies the mRNA expression of brain-derived neurotrophic factor in the hippocampus of adult mice
El-Sisi et al. Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia
Pillai et al. Metabotropic glutamate receptor 5–a promising target in drug development and neuroimaging
Terry Jr et al. Chronic exposure to typical or atypical antipsychotics in rodents: Temporal effects on central α7 nicotinic acetylcholine receptors
Min et al. Neuregulin-1 prevents amyloid β-induced impairment of long-term potentiation in hippocampal slices via ErbB4
Komleva et al. Expression of NLRP3 inflammasomes in neurogenic niche contributes to the effect of spatial learning in physiological conditions but not in Alzheimer’s type neurodegeneration
Bristow et al. Preclinical characterization of (R)-3-((3S, 4S)-3-fluoro-4-(4-hydroxyphenyl) piperidin-1-yl)-1-(4-methylbenzyl) pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-d-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder
Leung et al. Microglia activation mediates fibrillar amyloid-β toxicity in the aged primate cortex
Trujillo-Estrada et al. SPG302 Reverses synaptic and cognitive deficits without altering amyloid or tau pathology in a transgenic model of Alzheimer’s disease
KR102776570B1 (ko) 인지 기능을 향상시키기 위한 H3K9me3 조절의 용도
Xu et al. Epidemiology of Alzheimer’s disease
Beretta et al. Rescuing epileptic and behavioral alterations in a Dravet syndrome mouse model by inhibiting eukaryotic elongation factor 2 kinase (eEF2K)
Figueiredo et al. Alpha-linolenic acid treatment reduces the contusion and prevents the development of anxiety-like behavior induced by a mild traumatic brain injury in rats